Alpha memo: Resveratrol-plus-exercise effects may not translate cleanly from mature SAMP8 mouse liver to older adults' TMAO and cardiovascular markers; **One-sentence alpha:** A mechanistic anti-aging signal from resveratrol plus exercise training in SAMP8 mouse liver does not necessarily imply a parallel TMAO/cardiovascular benefit in older adults, and human evidence suggests the combined effect may be modest, dose-dependent, or context-specific. **Receipt 1:** Combination resveratrol with exercise training has anti-aging function only at mature stage SAMP8 mice liver (2023) - reports that 6-month-old SAMP8 mice receiving habitual exercise training plus resveratrol showed lower adipocytes, collagen, and apoptosis in liver cross-sections than 3-month-old counterparts, with molecular changes in PI3K/Akt/Bad/Bcl-2/cytochrome c and ERK/STAT3/IL-6/FGF2/MMP2 pathways consistent with an anti-apoptotic, anti-fibrotic hepatic signal at the mature stage. **Receipt 2:** Effects of resveratrol on changes in trimethylamine-N-oxide and circulating cardiovascular factors following exercise training among older adults (2024) - in 41 older adults (mean age ~72 y) doing 12 weeks of supervised multi-component training randomized to 500 mg/d resveratrol, 1000 mg/d resveratrol, or placebo, the trial examined dose-dependent changes in circulating TMAO and related metabolites and did not establish a robust, consistent resveratrol-plus-exercise benefit on TMAO/CVD markers in humans. **Why this is surprising:** Receipt 1 made plausible the expectation that combining resveratrol with exercise yields a coherent anti-aging/adaptation signal in a mammalian model, whereas Receipt 2 suggests that in older humans under a real exercise program, adding resveratrol does not clearly improve a gut-derived cardiovascular metabolite outcome, indicating the anchor can split across species and endpoint. **Caveats/falsifiers:** Receipt 1 is limited to SAMP8 mice at 3 vs 6 months, hepatic histology and selected signaling proteins, with no human, CVD, or TMAO readout; Receipt 2 is limited to n=41 adults ~72 y old, a 12-week multi-component program at 2×/week 80 min, fixed 500/1000 mg/day doses, and circulating TMAO-related metabolites, so it cannot test hepatic aging, long-term CVD events, or other tissues. A decisive falsifier would be a larger, longer human RCT in older adults showing that resveratrol (at 500 - 1000 mg/d) added to structured exercise produces a clear, dose-dependent reduction in TMAO and downstream CVD biomarkers that mirrors the mouse hepatic anti-aging signature.

Include the actual source for the 2023 SAMP8 mouse liver study in the source bundle to ground the first half of the contrast.